Alexion Pharmaceuticals Stock News

These two rare-disease drug developers are experts at penetrating their markets.

The short interest data are out for October 15, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential

These two companies are well-positioned to deliver market-beating returns for years to come.

Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alexion (ALXN) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Oct 29.

BOSTON--(BUSINESS WIRE)--Alexion to Report Third Quarter 2020 Results on Thursday, October 29, 2020

The health care strategy analyst at Jefferies said he expects to see acquisitions in the pharma and biotech space in the $5 billion to $10 billion range, according to an article in FierceBiotech. The

Earnings season is upon us and investors are pining for information about which stocks and sectors will do well.

With a strong grip on its target markets and a promising pipeline, this company should continue to grow.

Alexion (ALXN) gets FDA approval for Ultomiris 100 mg/mL, a new advanced formulation for the treatment of adults with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

The short interest data are out for September 30, the most recent settlement date.

BOSTON--(BUSINESS WIRE)--Alexion Receives FDA Approval for New Advanced Formulation of ULTOMIRIS® (ravulizumab-cwvz) with Significantly Reduced Infusion Time

BOSTON--(BUSINESS WIRE)--Alexion Announces Upcoming Data Presentations at the American Society of Nephrology’s Virtual Kidney Week 2020

With earnings season about to kick off, investors are being forced into a different sort of earnings season.

Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.